Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Yunpeng Liu
- Target Recruit Count
- 38
- Registration Number
- NCT06480864
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, China
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Zhangzhou Municipal Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06478264
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 620
- Registration Number
- NCT06467357
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06465563
- Locations
- 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06457503
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT06452277
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06446388
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 30
- Registration Number
- NCT06446726
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Zachary Zumsteg
- Target Recruit Count
- 50
- Registration Number
- NCT06445114
- Locations
- 🇺🇸
Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸CS Cancer at Valley Oncology Medical Group, Tarzana, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.